When was $BCYC first mentioned on Surfaced?

The earliest tracked mention of $BCYC in the Surfaced archive was on Mar 15, 2026.

How many voices track $BCYC?

2 FinTwit voices have mentioned $BCYC 6 times in the past 12 months.

What kind of voices mention $BCYC most?

$BCYC is mentioned most by Long Research voices on Surfaced.

Last 12mo stats

mentions

voices

$BCYC

Q: Who mentions $BCYC most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $BCYC most — 4 mentions in the past 12 months.

Bicycle Therapeutics Plc

$BCYC

Bicycle Therapeutics Plc

Past 12mo:6mentions2voices

All voices6 mentions since Mar 2026calls only

Loading price chart…

About this stock

$BCYC has received 6 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on March 15, 2026. @investmentguru_ is the most active voice discussing the stock with 4 mentions, while @jacobplieth has contributed 2 mentions. The most recent mention occurred on April 1, 2026. Long research content comprises the dominant category of discussion for this ticker among these voices.

AI-generated from tracked posts · updated Jul 10, 2026

Frequently asked

Who mentions $BCYC most on Surfaced?

Related stocks

$CATXPerspective Therapeutics

$CGONCg Oncology

$ZYMEZymeworks BC

$ARWRArrowhead Pharmaceuticals

Recent mentions

6 mentions

@investmentguru_Apr 1, 2026 · 10:51 AM

High Risk / High Reward Stocks Under $5 $RR → Robotics $PLUG → Clean Energy (Hydrogen) $INDI → Semiconductors (Auto AI) $SIVEF → Photonics / 5G $VLN → Semiconductors $SIDU → Space Technology $LASE → Photonics / Industrials $ZENA → Drones & Defense AI $BITF → AI infrastructure $OPEN → 🏠PropTech / Real Estate T $BULL → Financial Services / Fintech $EOSE → Energy Storage $MVST → EV Batteries / 🔋 storage $DFLI → Energy Storage (Solid-State) $ABCL → Biotech (Antibody Discovey $PRME → Biotech (Gene Editing) $TE → Energy solar $BTQ → Quantum Computing $EVTL → eVTOL / Electric Aviation $RXRX → AI Drug Discovery / Biotech $GRAB → Super App / Fintech $BBAI → Defense AI $BTG → Gold Mining $DGXX → AI Infrastructure $BCYC → 🧬 Biotech Not financial advice. DYOR.

Open on X

@jacobpliethMar 18, 2026 · 4:24 PM

$MRK's PD-1 x VEGF bispecific reveal, & other key #AACR26 presentations, via @APEXONCO -> https://t.co/ob1eswxCWF $RVMD $AMGN $GILD $BCYC $SDGR

Open on X

@jacobpliethMar 17, 2026 · 12:37 PM

As ever, I did warn you. You're welcome! $BCYC

Open on X

@investmentguru_Mar 16, 2026 · 5:17 PM

$BCYC

Open on X

@investmentguru_Mar 15, 2026 · 12:34 PM

$BCYC is one of the most interesting peptide biotech companies today Biotech innovation is entering a new phase where peptides are becoming powerful precision drugs. One company at the forefront of this trend is Bicycle Therapeutics. Technology: Bicyclic Peptides Bicycle Therapeutics developed a platform called “Bicycle molecules.” These are synthetic bicyclic peptides designed to combine the advantages of: • antibodies (high specificity) • small molecules (better tissue penetration) This allows drugs to reach tumors faster and more precisely. Core Strategy The company is focused on targeted cancer therapies using: Bicycle Drug Conjugates (BDC) These peptides deliver toxic payloads directly to cancer cells, minimizing damage to healthy tissue. Lead Drug Candidate Zelenectide Pevedotin (BT8009) Target: Nectin-4 receptor Potential uses: • bladder cancer • lung cancer • breast cancer This is particularly important because Nectin-4 is already a validated target used by blockbuster cancer drugs. Market Opportunity The antibody-drug conjugate / targeted oncology market is projected to exceed $50B+ this decade. If Bicycle’s technology works: • multiple oncology drugs could be developed • platform could attract big pharma partnerships or acquisition Key Catalysts • Phase 2 clinical trial results • additional oncology pipeline updates • expansion into radiopharmaceutical peptides Risks Like most clinical-stage biotech companies: • no approved drugs yet • heavy R&D spending • trial results drive stock volatility Cash in hand • $600 million plus Investment Perspective If even one oncology drug succeeds, the company could transition from sub-$1B biotech to multi-billion oncology platform. For investors interested in next-generation cancer therapeutics, $BCYC is worth watching. Not a financial advice. DYOR

Open on X

@investmentguru_Mar 15, 2026 · 12:22 PM

6 Peptide Biotech Stocks to watch for future. $BCYC •Tumor-targeting bicyclic peptides •Oncology + peptide-drug conjugates •Could attract major pharma buyouts if trials succeed $ENTX •Oral peptide delivery—no injections needed •Osteoporosis & metabolic disease drugs •Potential to disrupt $100B injectable peptide market $LSTA •Peptides that help chemotherapy drugs penetrate tumors •Oncology-focused with Phase 2/3 catalysts $CUE •Peptide-MHC molecules activate immune cells •Precision immunotherapy for cancer & autoimmune diseases $VTGN •Neuropeptide nasal sprays •Rapid-acting treatments for social anxiety disorder •Huge potential psychiatric market if trials succeed $PEPG •Peptide-enhanced delivery of RNA therapies •Focus on rare genetic diseases, e.g., Duchenne muscular dystrophy •Solves one of biotech’s biggest challenges: getting therapies inside cells efficiently •Could become a major platform play if delivery technology proves successful The peptide revolution is already underway: •GLP-1 drugs proved the market is massive •AI-designed peptides accelerate drug discovery •Small-cap peptide biotech companies often become multi-bagger winners after clinical successes High risk, high reward — clinical-stage biotechs are volatile. But the next biotech cycle could be defined by peptides.

Open on X